Pulmonx (LUNG) Total Non-Current Liabilities (2019 - 2025)

Pulmonx's (LUNG) quarterly Total Non-Current Liabilities came in at $75.2 million in Q4 2025, up 94.15% on a QoQ basis from $38.7 million in Q3 2022.

Pulmonx (LUNG) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends

Pulmonx (LUNG) has 5 years of Total Non-Current Liabilities data on file, last reported at $75.2 million in Q4 2025.

On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $75.2 million in Q4 2025; TTM through Dec 2025 was $75.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $75.2 million, changed N/A from the prior year.
Total Non-Current Liabilities for Q4 2025 stood at $75.2 million, up from $38.7 million in the prior quarter.
Over the last five years, Total Non-Current Liabilities for LUNG reached as high as $75.2 million in Q4 2025 and fell as low as $38.7 million in Q3 2022.
Historically, Total Non-Current Liabilities has averaged $47.3 million across 3 years, with a median of $40.5 million in 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	20.94 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	41.44 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	41.88 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	2.64 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	3.53 Bn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	9.85 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	24.21 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	3.57 Bn
10	Pulmonx	49.94 Mn	-19.81 Mn	-	75.18 Mn

Download Data